Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewBromocriptine mesylate
Description: D2-like agonist (D2>D3>D4)
Chemical Name: (5'a)-2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione mesylate
Purity: ≥98% (HPLC)
Biological Activity for Bromocriptine mesylate
Bromocriptine mesylate is a selective D3 and D2 dopamine receptor agonist (Ki values are ~ 5 nM and ~ 8 nM respectively). Activates both isoforms of D2 receptor (EC50 values are 0.10-0.12 nM and 4.4 nM for D2L and D2S receptors, respectively. Bromocriptine shows anti-Aβ effects that are increased in combination with Cromolyn (Cat. No. 6424) and Topiramate (Cat. No. 3620). Also lowers glucose and increases insulin sensitivity in vivo.
Compound Libraries for Bromocriptine mesylate
Bromocriptine mesylate is also offered as part of the Tocriscreen FDA-Approved Drugs. Find out more about compound libraries available from Tocris.
Technical Data for Bromocriptine mesylate
| M. Wt | 750.7 |
| Formula | C32H40BrN5O5.CH3SO3H |
| Storage | Store at RT |
| Purity | ≥98% (HPLC) |
| CAS Number | 22260-51-1 |
| PubChem ID | 31100 |
| InChI Key | NOJMTMIRQRDZMT-GSPXQYRGSA-N |
| Smiles | [H][C@]4([C@@](N[C@]([C@H](C)C)5C(N([C@@]([H])(CC(C)C)C(N(CCC7)[C@@]76[H])=O)[C@@]6(O)O5)=O)=O)CN([C@](C3=C4)([H])CC1=C(Br)NC2=C1C3=CC=C2)C.CS(=O)(O)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Bromocriptine mesylate
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 75.07 | 100 |
Preparing Stock Solutions for Bromocriptine mesylate
The following data is based on the product molecular weight 750.7. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.33 mL | 6.66 mL | 13.32 mL |
| 5 mM | 0.27 mL | 1.33 mL | 2.66 mL |
| 10 mM | 0.13 mL | 0.67 mL | 1.33 mL |
| 50 mM | 0.03 mL | 0.13 mL | 0.27 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets for Bromocriptine mesylate
References for Bromocriptine mesylate
References are publications that support the biological activity of the product.
Aubner et al (1990) Bromocriptine produces decreases in cocaine self-administration in the rat. Neuropsychopharmacology 3 101 PMID: 2317262
Lieberman and Goldstein (1985) Bromocriptine in Parkinson disease. Pharmacol.Rev. 37 217 PMID: 3901046
Seeman and Van Tol (1994) DA receptor pharmacology. TiPS 15 264 PMID: 7940991
Traub et al (1985) The effects of chronic bromocri. treatment on behaviour and DA receptor binding in the rat striatum. Eur.J.Pharmacol. 118 147 PMID: 3936723
Kondo et al (2017) iPSC-based compound screening and in vitro trials identify a synergistic anti-amyloid β combination for Alzheimer's disease. Cell Rep. 21 2304 PMID: 29166618
Tavares et al (2021) Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in type 2 diabetes. Mol.Metab. 51 101241 PMID: 33933677
If you know of a relevant reference for Bromocriptine mesylate, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Bromocriptine mesylate, Bromocriptine mesylate supplier, Selective, D2-like, agonists, Dopamine, Non-Selective, Receptors, D3, D4, dopaminergic, insulin, glucose, Ab, Abeta, amyloid, alzheimers, antidiabetic, Non-selective, Amyloid, Beta, Peptides, 0427, Tocris Bioscience
3 Citations for Bromocriptine mesylate
Citations are publications that use Tocris products. Selected citations for Bromocriptine mesylate include:
Liberante et al (2016) Identification and validation of the DA agonist bromocri. as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia. Oncotarget 7 6609 PMID: 26735888
Jia et al (2013) Age-dependent regulation of synaptic connections by DA D2 receptors. Nat Neurosci 16 1627 PMID: 24121738
Pedersen et al (2021) A novel luminescence-based-β-arrestin recruitment assay for unmodified receptors. J Biol Chem 296 100503 PMID: 33684444
Do you know of a great paper that uses Bromocriptine mesylate from Tocris? Please let us know.
Reviews for Bromocriptine mesylate
There are currently no reviews for this product. Be the first to review Bromocriptine mesylate and earn rewards!
Have you used Bromocriptine mesylate?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.